CD4/CD8 Ratio and KT Ratio Predict Yellow Fever Vaccine Immunogenicity in HIV-Infected Patients

about

Lipidomic analysis of immune activation in equine leptospirosis and Leptospira-vaccinated horses.

P2860

Q52688310-808F1FE4-156B-4000-92AC-E946FEDD49F7

P2860

CD4/CD8 Ratio and KT Ratio Predict Yellow Fever Vaccine Immunogenicity in HIV-Infected Patients

Item

http://www.wikidata.org/entity/Q36219873

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

CD4/CD8 Ratio and KT Ratio Pre ...... icity in HIV-Infected Patients

@ast

CD4/CD8 Ratio and KT Ratio Pre ...... icity in HIV-Infected Patients

@en

type

Item

label

CD4/CD8 Ratio and KT Ratio Pre ...... icity in HIV-Infected Patients

@ast

CD4/CD8 Ratio and KT Ratio Pre ...... icity in HIV-Infected Patients

@en

prefLabel

CD4/CD8 Ratio and KT Ratio Pre ...... icity in HIV-Infected Patients

@ast

CD4/CD8 Ratio and KT Ratio Pre ...... icity in HIV-Infected Patients

@en

P1476

CD4/CD8 Ratio and KT Ratio Pre ...... icity in HIV-Infected Patients

@en

P2093

Anna Shoko Nishiya

http://www.w3.org/2001/XMLSchema#string

Dayane Alves Costa

http://www.w3.org/2001/XMLSchema#string

Ester Cerdeira Sabino

http://www.w3.org/2001/XMLSchema#string

Helio H Caiaffa-Filho

http://www.w3.org/2001/XMLSchema#string

Juliana Zanatta C Dias

http://www.w3.org/2001/XMLSchema#string

Karina T Miyaji

http://www.w3.org/2001/XMLSchema#string

Marcos S Freire

http://www.w3.org/2001/XMLSchema#string

Marisa A Hong

http://www.w3.org/2001/XMLSchema#string

Marisol Simoes

http://www.w3.org/2001/XMLSchema#string

Natalia B Cerqueira

http://www.w3.org/2001/XMLSchema#string

P2860

Yellow fever vaccine for patients with HIV infection

Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies

Immune activation alters cellular and humoral responses to yellow fever 17D vaccine

HIV-infected individuals with low CD4/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality.

Adverse event reports following yellow fever vaccination.

Residual immune dysregulation syndrome in treated HIV infection.

The kynurenine pathway of tryptophan catabolism, CD4+ T-cell recovery, and mortality among HIV-infected Ugandans initiating antiretroviral therapy.

Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection.

Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment.

Yellow Fever Vaccine Booster Doses: Recommendations of the Advisory Committee on Immunization Practices, 2015.

P304

e0005219

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PNTD.0005219

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Esper G Kallas

Ana M Sartori

Vivian Iida Avelino-Silva

P577

2016-12-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27941965

http://www.w3.org/2001/XMLSchema#string

P921

yellow fever virus

P932

5179051

http://www.w3.org/2001/XMLSchema#string

CD4/CD8 Ratio and KT Ratio Predict Yellow Fever Vaccine Immunogenicity in HIV-Infected Patients

about

P2860

P2860

CD4/CD8 Ratio and KT Ratio Predict Yellow Fever Vaccine Immunogenicity in HIV-Infected Patients

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P932